8-K: INmune Bio's XPro Shows Cognitive and Biological Benefits in Subset of Early Alzheimer's Patients, Advances Towards Breakthrough Designation

INmune Bio announced topline Phase 2 MINDFuL trial results for XPro in early Alzheimer's disease, showing benefits in a predefined inflammatory subpopulation despite not meeting the primary endpoint in the broader cohort, and plans to seek Breakthrough Therapy Designation.

Summary

• INmune Bio's Phase 2 MINDFuL trial for XPro in early Alzheimer's Disease (AD) did not meet its primary cognitive endpoint (EMACC) in the modified intent-to-treat (mITT) population of 200 patients.
• In a predefined subpopulation of 100 amyloid-positive early AD patients with two or more biomarkers of inflammation, XPro treatment showed a cognitive benefit on the primary endpoint EMACC (effect size: 0.27) and the secondary endpoint Neuropsychiatric Inventory (effect size: -0.24).
• A biological benefit was also observed in this subpopulation, with a reduction in blood levels of pTau217 (effect size: -0.20), a gold standard measure of AD pathology.
• XPro was well-tolerated and safe, with no occurrences of ARIA-E or ARIA-H, even in high-risk ApoE4+/+ patients.
• The most common adverse events were injection site reactions (80% in XPro group vs. <20% in placebo), leading to discontinuation in 10 out of 14 patients who stopped treatment in the XPro arm.
• The company plans to present additional analyses at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025.
• INmune Bio intends to file for Breakthrough Therapy Designation with the FDA and schedule an End-of-Phase 2 meeting with the FDA in Q4 2025 to define the path for a pivotal trial.
• The company also provided updates on its other platforms: CORDStrom for Recessive Dystrophic Epidermolysis Bullosa (RDEB), which completed a Phase 2 trial showing itch improvement and other benefits, with plans for BLA/MAA submission in 1H 2026; and INKmune for metastatic castration-resistance prostate cancer (mCRPC), which is in an ongoing Phase I/II trial showing NK cell activation and tumor lesion regression.

Sentiment

Score: 6

Explanation: While the primary endpoint for XPro in the broad Alzheimer's population was not met, significant positive signals were observed in a predefined subpopulation with inflammation, demonstrating cognitive, behavioral, and biological benefits. The safety profile was favorable. Updates on other promising programs (CORDStrom and INKmune) also contribute positively. However, the overall primary endpoint miss for XPro is a notable negative.

Positives

• XPro demonstrated cognitive, behavioral, and biological benefits in a predefined subpopulation of early AD patients with inflammation (n=100), with effect sizes of 0.27 (EMACC), -0.24 (NPI), and -0.20 (pTau217).
• XPro treatment was safe and well-tolerated, with no ARIA-E or ARIA-H observed, even in high-risk ApoE4+/+ patients.
• The study validates targeting neuroinflammation as a driver of AD pathology.
• CORDStrom Phase 2 trial for RDEB showed beneficial effects on itch (a clinically meaningful endpoint), iscorEB clinician score, skin score, and quality of life, with a favorable safety profile.
• CORDStrom has Rare Pediatric Disease and Orphan Drug Designation, qualifying for a Priority Review Voucher post-FDA approval.
• INKmune Phase I/II trial in mCRPC showed evidence of in-vivo NK cell activation and regression of some tumor lesions by PSMA-PET.

Negatives

• The Phase 2 MINDFuL trial did not meet its primary cognitive endpoint (EMACC) in the overall modified intent-to-treat (mITT) population (n=200).
• Injection site reactions were common (80% in XPro group compared to <20% in placebo) and were the cause of discontinuation for 10 out of 14 patients who discontinued from the XPro arm.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• The availability of substantial additional funding is required for the company to continue its operations and to conduct research and development, clinical studies, and future product commercialization.
• There is no assurance that XPro, CORDstrom, or INKmune will be approved by the US Food and Drug Administration (FDA) or any regulatory body.
• The company's ability to produce more drug for clinical trials.
• Risks and uncertainties related to the company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Future Outlook

The company plans to advance XPro for early Alzheimer's disease by seeking Breakthrough Therapy Designation and scheduling an End-of-Phase 2 meeting with the FDA in Q4 2025 to define the path for a pivotal trial, while also engaging regulatory authorities in other regions. For CORDStrom, the company aims to file a Biologics License Application (BLA) in the US and a Marketing Authorization Application (MAA) in the UK/EU in the first half of 2026. The INKmune program is continuing its Phase I/II trial in mCRPC, with enrollment expected to complete in Q1 2026.

Management Comments

• "Our findings indicate that XPro may offer benefits to Alzheimers patients across all age groups, regardless of comorbidities, additional medications, or ApoE4 status. This evidence lays the foundation for advancing XPro as a promising treatment option for Alzheimers disease." RJ Tesi, MD, CEO.
• "By targeting neuroinflammation, a key driver of Alzheimers disease progression, XPro offers a novel mechanism to potentially slow disease progression and cognitive symptoms for persons living with Alzheimers disease and inflammation. The continued development of this therapeutic, whether as a standalone treatment or in combination with other therapies, holds promise in addressing this critical and growing unmet medical need." CJ Barnum, PhD, VP of CNS Drug Development.

Industry Context

The announcement relates to the growing interest in neuroinflammation as a disease-modifier in Alzheimer's disease and neurodegeneration. XPro's novel mechanism, selectively inhibiting soluble TNF, positions it within the broader landscape of AD treatments, which increasingly includes therapies targeting specific disease drivers beyond amyloid. The success in a predefined inflammatory subpopulation highlights a precision medicine approach, aligning with trends in drug development to identify patient populations most likely to respond. The RDEB market is also highlighted as an ultra-rare genetic disease with significant unmet need, with a competitor (Krystal Biotech's VYJUVEK) having an impressive launch, suggesting a viable market for CORDStrom.

Comparison to Industry Standards

• Dr. Judith Jaeger, a leading expert in cognitive assessment, states that absolute effect sizes of 0.2 or greater are considered preliminary evidence of potential therapeutic efficacy and are informative for signal detection in early phase AD studies. XPro achieved effect sizes of 0.27 (EMACC), -0.24 (NPI), and -0.20 (pTau217) in the responsive subpopulation, consistently meeting or exceeding this benchmark across multiple parameters.
• Krystal Biotech's VYJUVEK launch in DEB (Dystrophic Epidermolysis Bullosa) generated approximately $84 million net revenue in Q3 2024, indicating a significant market for RDEB treatments. CORDStrom is positioned as potentially the first systemic therapy for RDEB, with itch benefit as a key differentiating factor, and potential for use as an adjunctive therapy, aiming for a >$1 billion peak sales opportunity in the US, UK, and EU.

Stakeholder Impact

• Shareholders: Mixed impact due to primary endpoint miss but strong subpopulation data for XPro, and positive updates on other pipeline assets. Potential for future value creation if XPro gains Breakthrough Therapy Designation and advances, or if CORDStrom and INKmune succeed.
• Patients (Early AD with inflammation): Potential new therapeutic option (XPro) that targets neuroinflammation, offering cognitive, behavioral, and biological benefits.
• Patients (RDEB): Potential for a systemic therapy (CORDStrom) that could improve itch and other symptoms, addressing a significant unmet need.
• Patients (mCRPC): Potential for a novel NK cell-priming therapy (INKmune) showing early signs of tumor regression.
• Regulatory Authorities (FDA, EMA, MHRA): Will be engaged for Breakthrough Therapy Designation, End-of-Phase 2 meetings, and BLA/MAA submissions.

Next Steps

• Present additional analyses from the MINDFuL trial at AAIC in Toronto, Canada (July 27-31, 2025).
• File for Breakthrough Therapy Designation with the FDA for XPro.
• Schedule an End-of-Phase 2 meeting with the FDA in Q4 2025 to define the path for a pivotal trial to support XPro approval in early AD.
• Engage regulatory authorities in the UK, EU, and other regions in parallel for XPro.
• Compile and file Biologics License Application (BLA) in US & Marketing Authorization Application (MAA) in UK/EU for CORDStrom in 1H 2026.
• Complete Phase 2 mCRPC enrollment for INKmune in Q1 2026.

Key Dates

Recommendation

Keywords

Alzheimer's Disease, Neuroinflammation, XPro, MINDFuL trial, Phase 2, Biotechnology, Clinical trial, Drug development, Soluble TNF inhibitor, EMACC, pTau217, Breakthrough Therapy Designation, Recessive Dystrophic Epidermolysis Bullosa, RDEB, CORDStrom, Mesenchymal Stromal Cells, Orphan Drug Designation, Natural Killer cells, INKmune, Metastatic Castration-Resistance Prostate Cancer, mCRPC, Innate immune system, INMB